Revalida nanoventure

Revalida, a nanotech venture created by several Vanderbilt faculty members, is about to tap investors for its first outside capital, in a move to advance treatment of eye diseases, cancer and other problems. The story's here.

Fate of Compliant license uncertain

We reported on Compliant Therapeutics hopes for a license for Vanderbilt nanotechnology, but by midday that had clearly been threatened. Entrepreneur Eric Elmquist has other plans, but none perhaps so immediately compelling as this starter idea. There may've been a miscue, somewhere along the road. Read about it here.